Drug Trial Radar · NCT01989572
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
815
Actual
Start
Feb 23, 2000
Primary completion
Oct 8, 2012
Study completion Jan 31, 2013
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has been removed by surgery. Sargramostim may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether yeast derived sargramostim and vaccine therapy are more effective alone or together in preventing recurrence of melanoma.
Conditions
- Iris Melanoma
- Medium/Large Size Posterior Uveal Melanoma
- Mucosal Melanoma
- Ocular Melanoma With Extraocular Extension
- Recurrent Melanoma
- Recurrent Uveal Melanoma
- Small Size Posterior Uveal Melanoma
- Stage IIA Cutaneous Melanoma AJCC v6 and v7
- Stage IIA Uveal Melanoma AJCC v7
- Stage IIB Cutaneous Melanoma AJCC v6 and v7
- Stage IIB Uveal Melanoma AJCC v7
- Stage IIC Cutaneous Melanoma AJCC v6 and v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIA Uveal Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIB Uveal Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IIIC Uveal Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker AnalysisOther
Correlative studies
PlaceboOther
Given GM-CSF placebo SC
PlaceboOther
Given peptide placebo SC
SargramostimBiological
Given SC
Tyrosinase PeptideBiological
Given SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if >5 years, up to year 15
- Recurrence Free SurvivalTime frame: assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if >5 years, up to year 15
Locations
148 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Mobile Infirmary Medical Center
Mobile, Alabama
Mayo Clinic in Arizona
Scottsdale, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
City of Hope Comprehensive Cancer Center
Duarte, California
UC San Diego Moores Cancer Center
La Jolla, California
Saint Joseph Hospital - Orange
Orange, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
VA Palo Alto Health Care System
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Kaiser Permanente-San Diego Mission
San Diego, California
Naval Medical Center -San Diego
San Diego, California
Veterans Administration-San Diego Medical Center
San Diego, California
The Medical Center of Aurora
Aurora, Colorado
Boulder Community Hospital
Boulder, Colorado
SCL Health Saint Joseph Hospital
Denver, Colorado
Swedish Medical Center
Englewood, Colorado
Saint Mary's Hospital and Regional Medical Center
Grand Junction, Colorado
Manchester Memorial Hospital
Manchester, Connecticut
Southwest Florida Regional Medical Center
Fort Myers, Florida
Baptist MD Anderson Cancer Center
Jacksonville, Florida
Mayo Clinic in Florida
Jacksonville, Florida
Jupiter Medical Center
Jupiter, Florida
Lakeland Regional Health Hollis Cancer Center
Lakeland, Florida
Mount Sinai Medical Center
Miami Beach, Florida
AdventHealth Orlando
Orlando, Florida
Florida Cancer Specialists-West Palm Beach
West Palm Beach, Florida
Cleveland Clinic-Weston
Weston, Florida
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Augusta University Medical Center
Augusta, Georgia
Atlanta VA Medical Center
Decatur, Georgia
Eisenhower Army Medical Center
Fort Gordon, Georgia
Medical Center of Central Georgia
Macon, Georgia
South Georgia Medical Center/Pearlman Cancer Center
Valdosta, Georgia
Saint Luke's Mountain States Tumor Institute
Boise, Idaho
Rush - Copley Medical Center
Aurora, Illinois
Northwestern University
Chicago, Illinois
University of Chicago Comprehensive Cancer Center
Chicago, Illinois
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.